Pharmaceuticals, Biotechnology & Life Sciences

Discover how Bayer AG’s new debt‑reduction and capital‑injection strategy boosts R&D, mitigates litigation risks, and strengthens its global pharma position.

Explore how Novo’s “Novo” rebrand and €15bn share‑repurchase plan strengthen its leadership in GLP‑1 obesity treatments, amid rising oral competition.

Johnson & Johnson’s subcutaneous RYBREVANT FASPRO + LAZCLUZE combo shows far lower adverse events and VTE in EGFR‑mutated NSCLC, promising better patient safety, compliance and cost‑effective care.

Phase‑2 Japanese study starts on isavuconazole (Cresemba) for children at high risk of deep mycoses, aiming to secure pediatric approval and broaden antifungal options.

Explore how Palliser Capital’s critique of Recordati’s tender offer highlights undervaluation, board conflicts, and minority‑shareholder protection.

Explore how AstraZeneca’s oncology portfolio blends high‑impact hits like ENHERTU and TAGRISSO with strategic challenges in Etcamah, shaping future M&A and market access tactics.

Amgen’s Irish Open sponsorship shows how pharma uses high‑profile branding to boost market access, navigate patent cliffs, and target smart M&A in a competitive biotech landscape.

Sanofi and Regeneron highlight the social impact of atopic dermatitis, urging holistic care that blends clinical treatment with mental‑health support.

Semaglutide now treats MASH in China and shows strong pediatric obesity results, offering clinicians a versatile, safe, weight‑loss drug across ages.

Johnson & Johnson’s final PAPILLON trial data reveal RYBREVANT gives the longest overall survival for advanced NSCLC patients with EGFR exon 20 insertion mutations—36 months versus 24 months with chemo alone.